Liver transplantation for hepatocellular carcinoma-Factors influencing outcome and disease-free survival

World Journal of Gastroenterology

Volumn 21, Issue 42, 2015, Pages 12071-12082

  Fahrner, René ^a   Dondorf, Felix ^a   Ardelt, Michael ^a   Dittmar, Yves ^a   Settmacher, Utz ^a   Rauchfuß, Falk ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Diagnostics; Hepatocellular carcinoma; Liver transplantation; Recurrence; Risk factor; Survival

Indexed keywords

ALPHA FETOPROTEIN; MICRORNA; IMMUNOSUPPRESSIVE AGENT;

ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CHEMOEMBOLIZATION; CIRCULATING TUMOR CELL; DISEASE FREE SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; METABOLOMICS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROTEOMICS; RISK ASSESSMENT; TRANSCRIPTOMICS; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; LIVER NEOPLASMS; MORTALITY; PATHOLOGY; RISK FACTOR; TIME FACTOR; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84947425893     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i42.12071     Document Type: Article

References (170)

1. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35: 2155-2166 [PMID: 25752327 DOI: 10.1111/liv.12818]
2. Diamond DL, Proll SC, Jacobs JM, Chan EY, Camp DG, Smith RD, Katze MG. HepatoProteomics: applying proteomic technologies to the study of liver function and disease. Hepatology 2006; 44: 299-308 [PMID: 16871559 DOI: 10.1002/hep.21318]
3. Piras-Straub K, Khairzada K, Gerken G, Saner F, Treckmann J, Paul A, Canbay A, Herzer K. Glutamate dehydrogenase and alkaline phosphatase as very early predictors of hepatocellular carcinoma recurrence after liver transplantation. Digestion 2015; 91: 117-127 [PMID: 25662469 DOI: 10.1159/000370212]
4. Dutkowski P, Linecker M, DeOliveira ML, Müllhaupt B, Clavien PA. Challenges to liver transplantation and strategies to improve outcomes. Gastroenterology 2015; 148: 307-323 [PMID: 25224524 DOI: 10.1053/j.gastro.2014.08.045]
5. Varona MA, Soriano A, Aguirre-Jaime A, Garrido S, Oton E, Diaz D, Portero J, Bravo P, Barrera MA, Perera A. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. Transplant Proc 2015; 47: 84-89 [PMID: 25645778 DOI: 10.1016/j.transproceed.2014.12.013]
6. Pecchi A, Besutti G, De Santis M, Del Giovane C, Nosseir S, Tarantino G, Di Benedetto F, Torricelli P. Post-transplantation hepatocellular carcinoma recurrence: Patterns and relation between vascularity and differentiation degree. World J Hepatol 2015; 7: 276-284 [PMID: 25729483 DOI: 10.4254/wjh.v7.i2.276]
7. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]
8. Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg 2015; 220: 416-427 [PMID: 25690672 DOI: 10.1016/j.jamcollsurg.2014.12.0 25]
9. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403 [PMID: 11391528 DOI: 10.1053/jhep.2001.24563]
10. Tomasi TB. Structure and function of alpha-fetoprotein. Annu Rev Med 1977; 28: 453-465 [PMID: 67821 DOI: 10.1146/annurev. me.28.020177.002321]
11. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood) 2001; 226: 377-408 [PMID: 11393167]
12. Harper ME, Dugaiczyk A. Linkage of the evolutionarily-related serum albumin and alpha-fetoprotein genes within q11-22 of human chromosome 4. Am J Hum Genet 1983; 35: 565-572 [PMID: 6192711]
13. Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature 2008; 455: 1054-1056 [PMID: 18948945 DOI: 10.1038/4551054a]
14. Arakaki AK, Skolnick J, McDonald JF. Marker metabolites can be therapeutic targets as well. Nature 2008; 456: 443 [PMID: 19037294 DOI: 10.1038/456443c]
15. Gonzalez SA. Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? Hepatobiliary Surg Nutr 2014; 3: 410-414 [PMID: 25568864 DOI: 10.3978/j.issn.2304-3881.201 4.07.06]
16. Wang ZX, Jiang CP, Cao Y, Zhang G, Chen WB, Ding YT. Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2015; 14: 178-185 [PMID: 25865691]
17. Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS, Tsai YH, Huang YH. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Am J Gastroenterol 2015; 110: 836-844; quiz 845 [PMID: 25869392 DOI: 10.1038/ajg.2015.100]
18. Kim GA, Seock CH, Park JW, An J, Lee KS, Yang JE, Lim YS, Kim KM, Shim JH, Lee D, Lee HC. Reappraisal of serum alphafoetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver Int 2015; 35: 232-239 [PMID: 24576055 DOI: 10.1111/liv.12516]
19. Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 2014; 59: 986-995 [PMID: 24123097 DOI: 10.1002/hep.26739]
20. Shim JJ, Kim JW, Lee CK, Jang JY, Kim BH. Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B. J Gastroenterol Hepatol 2014; 29: 1699-1705 [PMID: 24730702 DOI: 10.1111/jgh.12612]
21. Chaiteerakij R, Zhang X, Addissie BD, Mohamed EA, Harmsen WS, Theobald PJ, Peters BE, Balsanek JG, Ward MM, Giama NH, Moser CD, Oseini AM, Umeda N, Venkatesh S, Harnois DM, Charlton MR, Yamada H, Satomura S, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2015; 21: 599-606 [PMID: 25789635 DOI: 10.1002/lt.24117]
22. Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. Clin Transplant 2015; 29: 506-512 [PMID: 25777321 DOI: 10.1111/ctr.12542]
23. Grąt M, Kornasiewicz O, Lewandowski Z, Hołówko W, Grąt K, Kobryń K, Patkowski W, Zieniewicz K, Krawczyk M. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg 2014; 38: 2698-2707 [PMID: 24858191 DOI: 10.1007/s00268-014-2647-3]
24. Guzman G, Alagiozian-Angelova V, Layden-Almer JE, Layden TJ, Testa G, Benedetti E, Kajdacsy-Balla A, Cotler SJ. p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol 2005; 18: 1498-1503 [PMID: 16007066 DOI: 10.1038/modpathol.3800458]
25. Freeman RB, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008; 8: 958-976 [PMID: 18336699 DOI: 10.1111/j.1600-6143.2008.02174.x]
26. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401 [PMID: 6306721 DOI: 10.1148/radiology.148.2.6306721]
27. Lesurtel M, Müllhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006; 6: 2644-2650 [PMID: 16939518 DOI: 10.1111/j.1600-6143.2006.01509.x]
28. Lau WY, Lai EC, Leung TW. Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review. Int J Radiat Oncol Biol Phys 2011; 81: 460-467 [PMID: 20888138 DOI: 10.1016/j.ijrobp.2010.06.010]
29. DuBay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, Ghanekar A, Guba M, Cattral MS, McGilvray ID, Grant DR, Greig PD. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford) 2011; 13: 24-32 [PMID: 21159100 DOI: 10.1111/j.1477-2574.2010.00228. x]
30. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012; 56 Suppl 1: S75-S87 [PMID: 22300468 DOI: 10.1016/S0168-8278(12)60009-9]
31. Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013; 19: 7515-7530 [PMID: 24282343 DOI: 10.3748/wjg.v19.i43.7515]
32. Molla N, AlMenieir N, Simoneau E, Aljiffry M, Valenti D, Metrakos P, Boucher LM, Hassanain M. The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol 2014; 21: e480-e492 [PMID: 24940108 DOI: 10.3747/co.21.1829]
33. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25 [PMID: 17103105 DOI: 10.1007/s00270-006-0062-3]
34. Galuppo R, McCall A, Gedaly R. The role of bridging therapy in hepatocellular carcinoma. Int J Hepatol 2013; 2013: 419302 [PMID: 24455285 DOI: 10.1155/2013/419302]
35. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Boudjema K, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouilleres O, Dhumeaux D, Cherqui D, Duvoux C. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11: 767-775 [PMID: 15973710 DOI: 10.1002/lt.20418]
36. Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol 2013; 58: 609-618 [PMID: 23041304 DOI: 10.1016/j.jhep.2012.09.021]
37. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, Margreiter R, Vogel W. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279 [PMID: 17256758 DOI: 10.1002/lt.21033]
38. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, Reig M, Bianchi L, Llovet JM, Bruix J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115: 616-623 [PMID: 19117042 DOI: 10.1002/cncr.24050]
39. Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, Kim DG, Choi JY. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010; 31: 415-423 [PMID: 19821808 DOI: 10.1111/j.1365-2036.2009.04167. x]
40. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, Margreiter R, Vogel W. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9: 557-563 [PMID: 12783395 DOI: 10.1053/jlts.2003.50106]
41. Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, Hoppe-Lotichius M, Schuchmann M, Victor A, Pitton M. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267 [PMID: 16826556 DOI: 10.1002/lt.20837]
42. Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, Lowell JA, Shenoy S, Darcy MD, Brown DB. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008; 248: 617-625 [PMID: 18936575 DOI: 10.1097/SLA.0b013e31818a07d4]
43. Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, De Simone P, Filipponi F, Bartolozzi C. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria-selection parameter for liver transplantation. Radiology 2010; 255: 289-300 [PMID: 20308465 DOI: 10.1148/radiol.09090927]
44. Li HL, Ji WB, Zhao R, Duan WD, Chen YW, Wang XQ, Yu Q, Luo Y, Dong JH. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis. World J Gastroenterol 2015; 21: 3599-3606 [PMID: 25834326 DOI: 10.3748/wjg.v21.i12.3599]
45. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and longterm survival. Hepatology 2010; 52: 1741-1749 [PMID: 21038413 DOI: 10.1002/hep.23944]
46. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-878 [PMID: 21618574 DOI: 10.1002/hep.24451]
47. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64 [PMID: 19766639 DOI: 10.1053/j.gastro.2009.09.006]
48. Iñarrairaegui M, Thurston KG, Bilbao JI, D'Avola D, Rodriguez M, Arbizu J, Martinez-Cuesta A, Sangro B. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1205-1212 [PMID: 20598574 DOI: 10.1016/j.jvir.2010.04.012]
49. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, Hunter RD, Nemcek AA, Abecassis MM, Haines KG, Salem R. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94: 572-586 [PMID: 17048240 DOI: 10.1002/jso.20609]
50. Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T, Mulcahy M, Nayar R, Lewandowski RJ, Salem R. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology 2013; 58: 1655-1666 [PMID: 23703789 DOI: 10.1002/hep.26487]
51. Saraswat VA, Pandey G, Shetty S. Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol 2014; 4: S80-S89 [PMID: 25755616 DOI: 10.1016/j.jceh.2014.05.004]
52. Fontana RJ, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl 2002; 8: 1165-1174 [PMID: 12474157 DOI: 10.1053/jlts.2002.36394]
53. Lu DS, Yu NC, Raman SS, Limanond P, Lassman C, Murray K, Tong MJ, Amado RG, Busuttil RW. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234: 954-960 [PMID: 15681691 DOI: 10.1148/radiol.2343040153]
54. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schiavo M, Garbagnati F, Marchianò A, Spreafico C, Camerini T, Mariani L, Miceli R, Andreola S. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240: 900-909 [PMID: 15492574]
55. Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352-1360 [PMID: 15565564 DOI: 10.1002/hep.20465]
56. Ashoori N, Paprottka P, Trumm C, Bamberg F, Kolligs FT, Rentsch M, Reiser MF, Jakobs TF. Multimodality treatment with conventional transcatheter arterial chemoembolization and radiofrequency ablation for unresectable hepatocellular carcinoma. Digestion 2012; 85: 18-26 [PMID: 22156507 DOI: 10.1159/000334714]
57. Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev 2013; 12: CD003046 [PMID: 24357457 DOI: 10.1002/14651858.CD003046.pub3]
58. Asman Y, Evenson AR, Even-Sapir E, Shibolet O. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma. Liver Transpl 2015; 21: 572-580 [PMID: 25644857 DOI: 10.1002/lt.24083]
59. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003; 226: 533-542 [PMID: 12563151 DOI: 10.1148/radiol.2262011980]
60. Wang XL, Li H, Wang QS, Zhang XL. Clinical value of preand postoperative 18F-FDG PET/CT in patients undergoing liver transplantation for hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xuebao 2006; 26: 1087-1091, 1095 [PMID: 16939890]
61. Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, Lee MC, Lee DS. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009; 50: 682-687 [PMID: 19372474 DOI: 10.2967/jnumed.108.060574]
62. Kornberg A, Freesmeyer M, Bärthel E, Jandt K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D, Settmacher U. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009; 9: 592-600 [PMID: 19191771 DOI: 10.1111/j.1600-6143.2008.02516.x]
63. Kornberg A, Küpper B, Thrum K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D. Increased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patients. Transplant Proc 2009; 41: 2561-2563 [PMID: 19715974 DOI: 10.1016/j.transproceed.2009.06.115]
64. Kornberg A, Küpper B, Tannapfel A, Büchler P, Krause B, Witt U, Gottschild D, Friess H. Patients with non-[18 F]fludeoxyglucoseavid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl 2012; 18: 53-61 [PMID: 21850692 DOI: 10.1002/lt.22416]
65. Cascales Campos P, Ramirez P, Gonzalez R, Febrero B, Pons JA, Miras M, Sanchez Bueno F, Robles R, Parrilla P. Value of 18-FDG-positron emission tomography/computed tomography before and after transarterial chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: initial results. Transplant Proc 2011; 43: 2213-2215 [PMID: 21839236 DOI: 10.1016/j.transproceed.2011.05.023]
66. Pant V, Sen IB, Soin AS. Role of 18F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma. Nucl Med Commun 2013; 34: 749-757 [PMID: 23689586 DOI: 10.1097/MNM.0b013e3283622eef]
67. Han JH, Kim DG, Na GH, Kim EY, Lee SH, Hong TH, You YK. Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma. World J Gastroenterol 2014; 20: 17132-17140 [PMID: 25493027 DOI: 10.3748/wjg.v20. i45.17132]
68. Ahn SY, Lee JM, Joo I, Lee ES, Lee SJ, Cheon GJ, Han JK, Choi BI. Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid-enhanced MR and (18)F-FDG PET/CT. Abdom Imaging 2015; 40: 843-851 [PMID: 25253426 DOI: 10.1007/s00261-014-0256-0]
69. Choi C, Seong J. Predictive factors of palliative radiotherapy response and survival in patients with spinal metastases from hepatocellular carcinoma. Gut Liver 2015; 9: 94-102 [PMID: 25071067 DOI: 10.5009/gnl14009]
70. Seo HJ, Kim GM, Kim JH, Kang WJ, Choi HJ. 18F-FDG PET/CT in hepatocellular carcinoma: detection of bone metastasis and prediction of prognosis. Nucl Med Commun 2015; 36: 226-233 [PMID: 25460306 DOI: 10.1097/MNM.0000000000000246]
71. Simoneau E, Hassanain M, Madkhali A, Salman A, Nudo CG, Chaudhury P, Metrakos P. (18)F-Fluorodeoxyglucose positronemission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. Curr Oncol 2014; 21: e551-e556 [PMID: 25089106 DOI: 10.3747/co.21.1959]
72. Lee JW, Yun M, Cho A, Han KH, Kim do Y, Lee SM, Lee JD. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Ann Nucl Med 2015; 29: 400-408 [PMID: 25652647 DOI: 10.1007/s12149-015-0956-8]
73. Ma W, Jia J, Wang S, Bai W, Yi J, Bai M, Quan Z, Yin Z, Fan D, Wang J, Han G. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics 2014; 4: 736-744 [PMID: 24883123 DOI: 10.7150/thno.8725]
74. Sabet A, Ahmadzadehfar H, Bruhman J, Sabet A, Meyer C, Wasmuth JC, Pieper CC, Biersack HJ, Ezziddin S. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. Nuklearmedizin 2014; 53: 39-45 [PMID: 24777354 DOI: 10.3413/Nukmed-0622-13-09]
75. Hayakawa N, Nakamoto Y, Nakatani K, Hatano E, Seo S, Higashi T, Saga T, Uemoto S, Togashi K. Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients. Int J Clin Oncol 2014; 19: 1020-1028 [PMID: 24366329 DOI: 10.1007/s10147-013-0653-3]
76. Song HJ, Cheng JY, Hu SL, Zhang GY, Fu Y, Zhang YJ. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clin Radiol 2015; 70: 128-137 [PMID: 25459673 DOI: 10.1016/j.crad.2014.09.020]
77. Ochi H, Hirooka M, Hiraoka A, Koizumi Y, Abe M, Sogabe I, Ishimaru Y, Furuya K, Miyagawa M, Kawasaki H, Michitaka K, Takada Y, Mochizuki T, Hiasa Y. (18)F-FDG-PET/CT predicts the distribution of microsatellite lesions in hepatocellular carcinoma. Mol Clin Oncol 2014; 2: 798-804 [PMID: 25054048 DOI: 10.3892/mco.2014.328]
78. Fahrner R, Beyoʇlu D, Beldi G, Idle JR. Metabolomic markers for intestinal ischemia in a mouse model. J Surg Res 2012; 178: 879-887 [PMID: 22947700 DOI: 10.1016/j.jss.2012.08.011]
79. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med 2011; 17: 448-453 [PMID: 21423183 DOI: 10.1038/nm.2307]
80. Sun JL, Zhang SK, Chen JY, Han BZ. Metabolic profiling of Staphylococcus aureus cultivated under aerobic and anaerobic conditions with (1)H NMR-based nontargeted analysis. Can J Microbiol 2012; 58: 709-718 [PMID: 22571732 DOI: 10.1139/w2012-046]
81. Wang X, Zhang A, Sun H. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology 2013; 57: 2072-2077 [PMID: 23150189 DOI: 10.1002/hep.26130]
82. Tsai TH, Song E, Zhu R, Di Poto C, Wang M, Luo Y, Varghese RS, Tadesse MG, Ziada DH, Desai CS, Shetty K, Mechref Y, Ressom HW. LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma. Proteomics 2015; 15: 2369-2381 [PMID: 25778709 DOI: 10.1002/pmic.201400364]
83. Darpolor MM, Basu SS, Worth A, Nelson DS, Clarke-Katzenberg RH, Glickson JD, Kaplan DE, Blair IA. The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and (13) C-isotope based metabolomics. NMR Biomed 2014; 27: 381-389 [PMID: 24497316 DOI: 10.1002/nbm.3072]
84. Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, Gonzalez FJ, Dufour JF, Idle JR. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 2011; 71: 6590-6600 [PMID: 21900402 DOI: 10.1158/0008-5472.CAN-11-0885]
85. Shao Y, Zhu B, Zheng R, Zhao X, Yin P, Lu X, Jiao B, Xu G, Yao Z. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery. J Proteome Res 2015; 14: 906-916 [PMID: 25483141 DOI: 10.1021/pr500973d]
86. Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X, Wang H, Xu G. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res 2013; 73: 4992-5002 [PMID: 23824744 DOI: 10.1158/0008-5472.CAN-13-0308]
87. Beyoʇlu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, Idle JR. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology 2013; 58: 229-238 [PMID: 23463346 DOI: 10.1002/hep.26350]
88. Taoka M, Morofuji N, Yamauchi Y, Ojima H, Kubota D, Terukina G, Nobe Y, Nakayama H, Takahashi N, Kosuge T, Isobe T, Kondo T. Global PROTOMAP profiling to search for biomarkers of earlyrecurrent hepatocellular carcinoma. J Proteome Res 2014; 13: 4847-4858 [PMID: 24967658 DOI: 10.1021/pr500262p]
89. Xu B, Wang F, Song C, Sun Z, Cheng K, Tan Y, Wang H, Zou H. Large-scale proteome quantification of hepatocellular carcinoma tissues by a three-dimensional liquid chromatography strategy integrated with sample preparation. J Proteome Res 2014; 13: 3645-3654 [PMID: 24972180 DOI: 10.1021/pr500200s]
90. Zhu Z, Zhang X, Wang G, Zheng H. Role of MicroRNAs in Hepatocellular Carcinoma. Hepat Mon 2014; 14: e18672 [PMID: 25337143 DOI: 10.5812/hepatmon.18672]
91. Li X, Yang W, Lou L, Chen Y, Wu S, Ding G. microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma. Dig Dis Sci 2014; 59: 1099-1107 [PMID: 24390674 DOI: 10.1007/s10620-013-3006-1]
92. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854 [PMID: 8252621]
93. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75: 855-862 [PMID: 8252622]
94. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866 [PMID: 17060945 DOI: 10.1038/nrc1997]
95. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-874 [PMID: 22094949 DOI: 10.1038/nrg3074]
96. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013; 12: 847-865 [PMID: 24172333 DOI: 10.1038/nrd4140]
97. Varnholt H. The role of microRNAs in primary liver cancer. Ann Hepatol 2008; 7: 104-113 [PMID: 18626426]
98. Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, Pan Z, Hu X, Zhao Y, Xie H, Jiang G, Chen T, Wang J, Zheng S, Cheng J, Wan D, Yang S, Li Y, Gu J. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008; 123: 1616-1622 [PMID: 18649363 DOI: 10.1002/ijc.23693]
99. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L, Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-6099 [PMID: 17616664 DOI: 10.1158/0008-5472.CAN-06-4607]
100. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD, Tsou AP. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009; 49: 1571-1582 [PMID: 19296470 DOI: 10.1002/hep.22806]
101. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-2545 [PMID: 16331254 DOI: 10.1038/sj.onc.1209283]
102. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14: 419-427 [PMID: 18223217 DOI: 10.1158/1078-0432.CCR-07-0523]
103. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-658 [PMID: 17681183 DOI: 10.1053/j.gastro.2007.05.022]
104. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, Croce CM. miR-221 & 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009; 16: 498-509 [PMID: 19962668 DOI: 10.1016/j.ccr.2009.10.014]
105. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009; 15: 5073-5081 [PMID: 19671867 DOI: 10.1158/1078-0432.CCR-09-0092]
106. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28: 3526-3536 [PMID: 19617899 DOI: 10.1038/onc.2009.211]
107. Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 2010; 16: 867-875 [PMID: 20103675 DOI: 10.1158/1078-0432.CCR-09-1840]
108. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011; 253: 745-758 [PMID: 21475015 DOI: 10.1097/SLA.0b013e3182111195]
109. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, Giulini SM. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243: 229-235 [PMID: 16432356 DOI: 10.1097/01.sla.0000197706.21803.a1]
110. Zhang Y, Li J, Cao L, Xu W, Yin Z. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol 2012; 39: 449-460 [PMID: 22846862 DOI: 10.1053/j.seminoncol.2012.05.012]
111. Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59: 110-118 [PMID: 23014601 DOI: 10.1373/clinchem.2012.194258]
112. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284 [PMID: 19308067 DOI: 10.1038/nrc2622]
113. Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant 2011; 11: 2031-2035 [PMID: 21831154 DOI: 10.1111/j.1600-6143.2011.03689. x]
114. Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics 2007; 4: 741-756 [PMID: 18067413 DOI: 10.1586/14789450.4.6.7 41]
115. Attard G, de Bono JS. Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev 2011; 21: 50-58 [PMID: 21112767 DOI: 10.1016/j.gde.2010.10.010]
116. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 1999; 188: 201-206 [PMID: 10398165]
117. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, Shi RY, Hu B, Zhou J, Fan J. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013; 57: 1458-1468 [PMID: 23175471 DOI: 10.1002/hep.26151]
118. Zhang Y, Shi ZL, Yang X, Yin ZF. Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis. World J Gastroenterol 2014; 20: 142-147 [PMID: 24415867 DOI: 10.3748/wjg.v20.i1.142]
119. Morris KL, Tugwood JD, Khoja L, Lancashire M, Sloane R, Burt D, Shenjere P, Zhou C, Hodgson C, Ohtomo T, Katoh A, Ishiguro T, Valle JW, Dive C. Circulating biomarkers in hepatocellular carcinoma. Cancer Chemother Pharmacol 2014; 74: 323-332 [PMID: 24923562 DOI: 10.1007/s00280-014-2508-7]
120. Liu HY, Qian HH, Zhang XF, Li J, Yang X, Sun B, Ma JY, Chen L, Yin ZF. Improved method increases sensitivity for circulating hepatocellular carcinoma cells. World J Gastroenterol 2015; 21: 2918-2925 [PMID: 25780289 DOI: 10.3748/wjg.v21.i10.2918]
121. Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME, Florman SS. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology 2015; 61: 895-904 [PMID: 25099130 DOI: 10.1002/hep.27358]
122. Kornberg A, Witt U, Kornberg J, Friess H, Thrum K. Extended Ischemia Times Promote Risk of HCC Recurrence in Liver Transplant Patients. Dig Dis Sci 2015; 60: 2832-2839 [PMID: 25630421 DOI: 10.1007/s10620-015-3541-z]
123. Croome KP, Wall W, Chandok N, Beck G, Marotta P, Hernandez-Alejandro R. Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl 2013; 19: 1214-1223 [PMID: 23907778 DOI: 10.1002/lt.23715]
124. Ozier Y, Albi A. Liver transplant surgery and transfusion. Int Anesthesiol Clin 2004; 42: 147-162 [PMID: 15205645]
125. Hendriks HG, van der Meer J, Klompmaker IJ, Choudhury N, Hagenaars JA, Porte RJ, de Kam PJ, Slooff MJ, de Wolf JT. Blood loss in orthotopic liver transplantation: a retrospective analysis of transfusion requirements and the effects of autotransfusion of cell saver blood in 164 consecutive patients. Blood Coagul Fibrinolysis 2000; 11 Suppl 1: S87-S93 [PMID: 10850571]
126. Navarro F, Le Moine MC, Fabre JM, Belghiti J, Cherqui D, Adam R, Pruvot FR, Letoublon C, Domergue J. Specific vascular complications of orthotopic liver transplantation with preservation of the retrohepatic vena cava: review of 1361 cases. Transplantation 1999; 68: 646-650 [PMID: 10507483]
127. Bennett-Guerrero E, Feierman DE, Barclay GR, Parides MK, Sheiner PA, Mythen MG, Levine DM, Parker TS, Carroll SF, White ML, Winfree WJ. Preoperative and intraoperative predictors of postoperative morbidity, poor graft function, and early rejection in 190 patients undergoing liver transplantation. Arch Surg 2001; 136: 1177-1183 [PMID: 11585512]
128. Coêlho GR, Feitosa Neto BA, de G Teixeira CC, Marinho DS, Rangel ML, Garcia JH. Single-center transfusion rate for 555 consecutive liver transplantations: impact of two eras. Transplant Proc 2013; 45: 3305-3309 [PMID: 24182806 DOI: 10.1016/j.trans proceed.2013.07.062]
129. de Boer MT, Christensen MC, Asmussen M, van der Hilst CS, Hendriks HG, Slooff MJ, Porte RJ. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 2008; 106: 32-44, table of contents [PMID: 18165548 DOI: 10.1213/01.ane.0000289638.26666.ed]
130. Cacciarelli TV, Keeffe EB, Moore DH, Burns W, Busque S, Concepcion W, So SK, Esquivel CO. Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation. Arch Surg 1999; 134: 25-29 [PMID: 9927126]
131. Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg 2012; 256: 235-244 [PMID: 22791100 DOI: 10.1097/SLA.0b013e31825b35d5]
132. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006; (1): CD005033 [PMID: 16437512 DOI: 10.1002/14651858. CD005033.pub2]
133. Burrows L, Tartter P. Effect of blood transfusions on colonic malignancy recurrent rate. Lancet 1982; 2: 662 [PMID: 6125797]
134. Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg 1993; 80: 427-432 [PMID: 8192723]
135. Vamvakas EC. Perioperative blood transfusion and cancer recurrence: meta-analysis for explanation. Transfusion 1995; 35: 760-768 [PMID: 7570938]
136. Schiergens TS, Rentsch M, Kasparek MS, Frenes K, Jauch KW, Thasler WE. Impact of perioperative allogeneic red blood cell transfusion on recurrence and overall survival after resection of colorectal liver metastases. Dis Colon Rectum 2015; 58: 74-82 [PMID: 25489697 DOI: 10.1097/DCR.0000000000000233]
137. Hallet J, Tsang M, Cheng ES, Habashi R, Kulyk I, Hanna SS, Coburn NG, Lin Y, Law CH, Karanicolas PJ. The Impact of Perioperative Red Blood Cell Transfusions on Long-Term Outcomes after Hepatectomy for Colorectal Liver Metastases. Ann Surg Oncol 2015; 22: 4038-4045 [PMID: 25752895 DOI: 10.1245/s10434-015-4477-4]
138. Shiba H, Ishida Y, Fujiwara Y, Wakiyama S, Gocho T, Ito R, Sakamoto T, Tsutsui N, lida T, Matsumoto M, Furukawa K, Haruki K, Hirohara S, Misawa T, Yanaga K. Practice to minimize the use of blood products improve outcome after hepatic resection for hepatocellular carcinoma. Hepatogastroenterology 2013; 60: 1681-1683 [PMID: 24634937]
139. Liu L, Wang Z, Jiang S, Shao B, Liu J, Zhang S, Zhou Y, Zhou Y, Zhang Y. Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a metaanalysis. PLoS One 2013; 8: e64261 [PMID: 23741309 DOI: 10.1371/journal.pone.0064261]
140. Zulim RA, Rocco M, Goodnight JE, Smith GJ, Krag DN, Schneider PD. Intraoperative autotransfusion in hepatic resection for malignancy. Is it safe? Arch Surg 1993; 128: 206-211 [PMID: 8381647]
141. Fujimoto J, Okamoto E, Yamanaka N, Oriyama T, Furukawa K, Kawamura E, Tanaka T, Tomoda F. Efficacy of autotransfusion in hepatectomy for hepatocellular carcinoma. Arch Surg 1993; 128: 1065-1069 [PMID: 8396388]
142. Liang TB, Li DL, Liang L, Li JJ, Bai XL, Yu W, Wang WL, Shen Y, Zhang M, Zheng SS. Intraoperative blood salvage during liver transplantation in patients with hepatocellular carcinoma: efficiency of leukocyte depletion filters in the removal of tumor cells. Transplantation 2008; 85: 863-869 [PMID: 18360269 DOI: 10.1097/TP.0b013e3181671f2e]
143. Muscari F, Suc B, Vigouroux D, Duffas JP, Migueres I, Mathieu A, Lavayssiere L, Rostaing L, Fourtanier G. Blood salvage autotransfusion during transplantation for hepatocarcinoma: does it increase the risk of neoplastic recurrence? Transpl Int 2005; 18: 1236-1239 [PMID: 16221153 DOI: 10.1111/j.1432-2277.2005.00207. x]
144. Akbulut S, Kayaalp C, Yilmaz M, Ince V, Ozgor D, Karabulut K, Eris C, Toprak HI, Aydin C, Yilmaz S. Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients. World J Gastroenterol 2013; 19: 1625-1631 [PMID: 23538988 DOI: 10.3748/wjg.v19.i10.1625]
145. Sotiropoulos GC, Molmenti EP, Lösch C, Beckebaum S, Broelsch CE, Lang H. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1, 198 cases. Eur J Med Res 2007; 12: 527-534 [PMID: 18024261]
146. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684 DOI: 10.1016/S0140-6736(00)04046-0]
147. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444 [PMID: 18650914 DOI: 10.1038/nature07205]
148. Xing T, Huang L, Yu Z, Zhong L, Wang S, Peng Z. Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma. PLoS One 2013; 8: e71251 [PMID: 23940730 DOI: 10.1371/journal. pone.0071251]
149. Lee JY, Kim YH, Yi NJ, Kim HS, Lee HS, Lee BK, Kim H, Choi YR, Hong G, Lee KW, Suh KS. Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol 2014; 20: 192-203 [PMID: 25032186 DOI: 10.3350/cmh.2014.20.2.192]
150. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-862 [PMID: 18948815 DOI: 10.1097/SLA.0b013e3181896278]
151. Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014; 27: 1039-1049 [PMID: 24943720 DOI: 10.1111/tri.12372]
152. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243 [PMID: 20187107 DOI: 10.1002/hep.23437]
153. Ferreiro AO, Vazquez-Millán MA, López FS, Gutiérrez MG, Diaz SP, Patiño MJ. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series. Transplant Proc 2014; 46: 3496-3501 [PMID: 25498079 DOI: 10.1016/j.transproceed.2014.08.045]
154. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37: 411-419 [PMID: 23278125 DOI: 10.1111/apt.12185]
155. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-8425 [PMID: 15623621 DOI: 10.1158/1078-0432.CCR-04-0941]
156. Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190 [PMID: 20459775 DOI: 10.1186/1471-2407-10-190]
157. Schlitt HJ, Schnitzbauer AA. Hepatocellular carcinoma: agents and concepts for preventing recurrence after curative treatment. Liver Transpl 2011; 17 Suppl 3: S10-S12 [PMID: 21850696 DOI: 10.1002/lt.22411]
158. Duvoux C, Kiuchi T, Pestalozzi B, Busuttil R, Miksad R. What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma? Liver Transpl 2011; 17 Suppl 2: S147-S158 [PMID: 21714065 DOI: 10.1002/lt.22367]
159. Fujiki M, Aucejo F, Kim R. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this? Clin Transplant 2013; 27: 169-177 [PMID: 23216662 DOI: 10.1111/ctr.12042]
160. Teng CL, Hwang WL, Chen YJ, Chang KH, Cheng SB. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. World J Surg Oncol 2012; 10: 41 [PMID: 22339891 DOI: 10.1186/1477-7819-10-41]
161. Shetty K, Dash C, Laurin J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma. J Transplant 2014; 2014: 913634 [PMID: 24818010 DOI: 10.1155/2014/913634]
162. Castelli G, Burra P, Giacomin A, Vitale A, Senzolo M, Cillo U, Farinati F. Sorafenib use in the transplant setting. Liver Transpl 2014; 20: 1021-1028 [PMID: 24809799 DOI: 10.1002/lt.23911]
163. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L, Zhao QC, Tian R, Feng Q, Zhang SH, Li Y, Jiang JL, Li L, Yu XL, Zhang Z, Chen ZN. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007; 45: 269-276 [PMID: 17256759 DOI: 10.1002/hep.21465]
164. Zhang Q, Chen H, Li Q, Zang Y, Chen X, Zou W, Wang L, Shen ZY. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Invest New Drugs 2011; 29: 1360-1369 [PMID: 21809025 DOI: 10.1007/s10637-011-9726-1]
165. Wu J, Sun H, Han Z, Peng Z. A single center experience: posttransplantation adjuvant chemotherapy impacts the prognosis of hepatocellular carcinoma patients. Chin Med J (Engl) 2014; 127: 430-434 [PMID: 24451946]
166. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43 [PMID: 19058754 DOI: 10.1016/S1470-2045(08)70284-5]
167. Takada Y, Uemoto S. Liver transplantation for hepatocellular carcinoma: the Kyoto experience. J Hepatobiliary Pancreat Sci 2010; 17: 527-532 [PMID: 19707711 DOI: 10.1007/s00534-009-0162-y]
168. Fan J, Zhou J, Xu Y, Qiu SJ, Wu ZQ, Yu Y, Huang XW, Tang ZY, Wang YQ. [Indication of liver transplantation for hepatocellular carcinoma: Shanghai Fudan Criteria]. Zhonghua Yixue Zazhi 2006; 86: 1227-1231 [PMID: 16796876]
169. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85: 1726-1732 [PMID: 18580463 DOI: 10.1097/TP.0b013e31816b67e4]
170. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008; 14: 935-945 [PMID: 18581465 DOI: 10.1002/lt.21445]